{"id":869748,"date":"2025-07-15T10:04:45","date_gmt":"2025-07-15T14:04:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/"},"modified":"2025-07-15T10:04:45","modified_gmt":"2025-07-15T14:04:45","slug":"bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/","title":{"rendered":"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic"},"content":{"rendered":"

<\/p>\n

bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic<\/b><\/p>\n

One third of world\u2019s smokers live in China, which has highest rate of lung cancer<\/i><\/b><\/p>\n

SAN ANTONIO–(BUSINESS WIRE<\/a>)–bioAffinity Technologies, Inc.<\/b><\/a> (Nasdaq: BIAF; BIAFW),<\/b> a biotechnology company advancing early-stage cancer diagnostics including CyPath\u00ae Lung<\/a>, the Company\u2019s commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry.<\/p>\n

\nChina represents a large prospective market for CyPath\u00ae Lung with more than 300 million people who smoke, or a third of the world\u2019s total smokers, according to the World Health Organization<\/a>. The China cancer registry estimated 1.06 million new cases of lung cancer were diagnosed in 2022.<\/p>\n

\n\u201cThis patent is another step forward in our strategy to safeguard and expand the reach of our proprietary diagnostic platform internationally,\u201d said Maria Zannes, President and CEO of bioAffinity Technologies. \u201cWith lung cancer representing a major health burden globally and particularly in China, securing this intellectual property positions us well for future opportunities in one of the world\u2019s largest and most underserved healthcare markets. It reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives.\u201d<\/p>\n

\nThe newly allowed Chinese patent\u2014titled \u201cSystem and Method for Determining Lung Health\u201d\u2014protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum.<\/p>\n

\nCyPath\u00ae Lung is the Company\u2019s first commercial product, with clinical study results<\/a> demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. In the study, CyPath\u00ae Lung detected all forms of lung cancer and 80% of cancers that were Stage 1.<\/p>\n

\nThis newly allowed patent complements bioAffinity\u2019s expanding global patent estate, which now includes multiple patents in the U.S, China, Japan, Australia, Mexico, Canada and the EU.<\/p>\n

About CyPath\u00ae Lung<\/b><\/p>\n

\nCyPath\u00ae<\/sup> Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath\u00ae Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results<\/a> demonstrated that CyPath\u00ae Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com<\/a>.<\/p>\n

About bioAffinity Technologies, Inc.<\/b><\/p>\n

\nbioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company\u2019s first product, CyPath\u00ae Lung<\/a>, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath\u00ae Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services<\/a>, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nCertain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company\u2019s ability to safeguard its intellectual property, and the ability to market the CyPath\u00ae Lung technology in China. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company\u2019s ability to derive benefits from the patent and other factors discussed in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250715047187\/en\/<\/a><\/span><\/p>\n

bioAffinity Technologies
\n<\/b>
Julie Anne Overton
\n
Director of Communications
\n
jao@bioaffinitytech.com
\n<\/a><\/p>\n

Investor Relations
\n<\/b>
Dave Gentry
\n
RedChip Companies Inc.
\n
1-800-RED-CHIP (733-2447) or 407-491-4498
\n
BIAF@redchip.com<\/a><\/p>\n

KEYWORDS:<\/b> Texas China United States North America Asia Pacific<\/p>\n

INDUSTRY KEYWORDS:<\/b> Technology Health Technology Software Biotechnology Other Health Health Data Management Artificial Intelligence Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic One third of world\u2019s smokers live in China, which has highest rate of lung cancer SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath\u00ae Lung, the Company\u2019s commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. China represents a large prospective market for CyPath\u00ae Lung with more than 300 million people who smoke, or a third of the world\u2019s total smokers, according to the World Health Organization. … <\/p>\n

Continue reading “bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-869748","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nbioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic One third of world\u2019s smokers live in China, which has highest rate of lung cancer SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath\u00ae Lung, the Company\u2019s commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. China represents a large prospective market for CyPath\u00ae Lung with more than 300 million people who smoke, or a third of the world\u2019s total smokers, according to the World Health Organization. … Continue reading "bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-15T14:04:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic\",\"datePublished\":\"2025-07-15T14:04:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/\"},\"wordCount\":919,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/\",\"name\":\"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-07-15T14:04:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/","og_locale":"en_US","og_type":"article","og_title":"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic - Market Newsdesk","og_description":"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic One third of world\u2019s smokers live in China, which has highest rate of lung cancer SAN ANTONIO–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath\u00ae Lung, the Company\u2019s commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. China represents a large prospective market for CyPath\u00ae Lung with more than 300 million people who smoke, or a third of the world\u2019s total smokers, according to the World Health Organization. … Continue reading \"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-15T14:04:45+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic","datePublished":"2025-07-15T14:04:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/"},"wordCount":919,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/","name":"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-07-15T14:04:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250715047187r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-announces-notification-of-china-patent-award-for-companys-noninvasive-lung-cancer-diagnostic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"bioAffinity Technologies Announces Notification of China Patent Award for Company\u2019s Noninvasive Lung Cancer Diagnostic"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=869748"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/869748\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=869748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=869748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=869748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}